The project involves a cumulative investment of $250 million over five years, covering research and development, infrastructure, and capital expenditures. The new plant will have the capacity to produce more than 25 essential respiratory medicines, including lifesaving albuterol inhalers for children with asthma and service members both domestically and overseas.
By boosting domestic manufacturing and diversifying the supply chain, Lupin aims to reinforce its position as a global leader in respiratory medicines. The initiative is also expected to generate over 200 long-term skilled jobs in Broward County by 2030, providing a local economic boost.
Also Read: Lupin receives OAI classification from USFDA for Pithampur Unit 2 manufacturing facility
Christoph Funke, Chief Technical Operations Officer, Lupin, said, "The expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy. This new state-of-the-art facility will build on our existing presence in Florida, which is home to Lupin's headquarters and our Advanced Inhalation Research Center."
The Coral Springs facility will anchor U.S. production of critical respiratory therapies, diversify the supply chain, and ensure affordable, reliable access—from routine pediatric care to pandemic-scale demand. Lupin has acquired more than 5 acres of land to embark on this expansion of 70,000 square feet.
In recognition of its investment and job creation plans, Lupin will receive tax credits and incentives from the state of Florida. Lupin is partnering with Florida Commerce/Select Florida, City of Coral Springs, Greater Fort Lauderdale Alliance, and Broward County Commission (Workforce/college partner) as part of this strategic project.
Also Read: Lupin launches blood sugar control injection in US
Shares of Lupin Ltd ended at ₹1,902.80, down by ₹22.00, or 1.14%, on the BSE.